Adiponectin through its biphasic serum level is a useful biomarker during transition from diastolic dysfunction to systolic dysfunction - an experimental study by Mingqiang Fu et al.
Fu et al. Lipids in Health and Disease 2012, 11:106
http://www.lipidworld.com/content/11/1/106RESEARCH Open AccessAdiponectin through its biphasic serum level is a
useful biomarker during transition from diastolic
dysfunction to systolic dysfunction - an
experimental study
Mingqiang Fu1†, Jingmin Zhou1†, Juying Qian1†, Xuejuan Jin1, Hongmin Zhu1, Chunlin Zhong1, Michael Fu2,
Yunzeng Zou1,3* and Junbo Ge1,3*Abstract
Background: Adiponectin is reported to relate with cardiovascular diseases, we sought to examine whether
adiponectin is associated with disease progression of heart failure from hypertension in rats in comparison with
other known biomarkers and echocardiographic parameters. Spontaneously hypertensive rats (SHR, n= 35), aged
1 month, were used and followed up to 18 months. High frequency echocardiography was performed both at
baseline and every 3 months thereafter. Moreover, serum levels of N-terminal pro-natriuretic peptide (NT-proBNP)
and interleukin-6 (IL-6) as well as serum level and tissue expression of adiponectin were determined at the same
time as echocardiography.
Results: The results clearly demonstrated time-dependent progression of hypertension and heart dysfunction as
evidenced by gradually increased left ventricular mass index, NT-proBNP, IL-6 as well as gradually decreased cardiac
function as assessed by echocardiography. Meanwhile, tissue and serum adiponectin decreased from 3 months and
reached plateau until 12 months in parallel with decreasing of cardiac diastolic function. Thereafter, adiponectin
levels increased prior to occurrence of systolic dysfunction. Adiponectin concentration is inversely related with
NT-proBNP, IL-6 and E/E0 (correlation coefficient (r) =−0.756 for NT-proBNP, p < 0.001, -0.635 for IL-6, p = 0.002, and
−0.626 for E/E0, p = 0.002, respectively) while positively correlated with E/A and E0/A0 (r = 0.683 for E/A, p = 0.001,
0.671 for E0/A0, p = 0.001, respectively). No difference for adiponectin distribution among visceral adipose tissues was
found.
Conclusion: Adiponectin through its biphasic serum level is a useful biomarker during transition from diastolic
dysfunction to systolic dysfunction.
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Adipose tissue has been long considered to be an energy-
storage compartment before discovery of the various
adipocytokines, such as adiponectin, leptin, plasminogen
activator inhibitor type 1 (PAI-1), interleukin(IL)-1β, IL-8,
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reproduction in any medium, provided the ormultiple biological activities and significantly contribute to
the regulation of the body’s homeostasis [3,4]. Notable
among these is adiponectin, an adipose-tissue-specific
plasma protein which is accounting for as much as 0.01%
of total plasma proteins [5].
Adiponectin, also referred to as Acrp30/AdipoQ/apM1/
GBP28, belongs to the collectin family [6] and contains
four structural domains based on its primary sequence: an
N-terminal signal peptide, a short hyper-variable region, a
collagen domain, and a C-terminal globular domain hom-
ologous to C1q [7]. Basic researches and clinical studiestd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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anti-atherogenic and anti-inflammatory properties [8-10]
but also had important protective effects at cardiovascular
level [11]. However, the role of adiponectin in the develop-
ment of cardiac diseases remains less clear than it does for
metabolic disorders. Initial evidence from clinical studies
showed that exposure to angiotensin II receptor blockers
increased circulating levels of adiponectin. Moreover, the
induction of hypertension with angiotensin II injection
leads to a decrease in plasma adiponectin concentration
concomitant with blood pressure elevation [12]. The associ-
ation between adiponectin and hypertension is also evident
in clinical studies by showing that hypoadiponectinemia is
a risk factor for hypertension independent of insulin resist-
ance and diabetes [13,14]. However, till to now, few stud-
ies address the time-frame changes of adiponectin during
transition from hypertension to onset of cardiac dysfunc-
tion and heart failure. Therefore, our hypothesis is that
adiponectin may serve as a useful biomarker for transition
from left ventricular hypertrophy to cardiac dysfunction
and heart failure. In this study, we examined whether
serum and tissue adiponectin levels are associated with
onset of heart failure from hypertension through left ven-
tricular hypertrophy in rats in comparison with other
known biomarkers for heart function and inflammation.Materials and methods
Animals
Thirty five male spontaneously hypertensive rats (SHR)
were purchased from Shanghai Laboratory Animal Center,
Chinese Academy Sciences at 2 weeks of age. All rats were
maintained in a specific pathogen-free room under condi-
tions of temperature- and humidity- controlled with a
12:12-h light–dark cycle and given standard laboratory
chow and tap water ad libitum. The starting age was
4 weeks. All of the animal experiments were performed in
compliance with the Guide for the Care and Use of La-
boratory Animals published by the US National Institutes
of Health (NIH Publication No. 85–23, revised 1996) and
was approved by the guidelines for animal research of
Zhongshan Hospital, Fudan University.Experimental protocol
SHR were weighed, and systolic blood pressure (SBP) and
heart rate (HR) were measured by a tail-cuff method (BP-
98A, Softron, Tokyo, Japan) while conscious at 1, 3, 6, 9, 12,
15 and 18 months of age, respectively. After body weight
(BW) and SBP data obtained, transthoracic high frequency
echocardiographic studies were conducted. Thereafter the
rats were sacrificed at each of the above time points to
measure the levels of serum NT-proBNP, IL-6 and adipo-
nectin, as well as the distribution and changes of adiponec-
tin in different visceral adipose tissues.Echocardiographic studies
SHR were anesthetized with intraperitoneal injection of
50 mg/kg ketamine hydrochloride, and an additional
0.1-0.3 ml was given if needed. Rats were allowed to
breathe spontaneously during the echocardiographic
studies with a mean heart rate at 393 ± 18 bpm.
After being anesthetized, the rats were transferred to a
heated platform and precordial region of the rats was
shaved and warmed acoustic coupling gel was applied.
Subsequently, transthoracic echocardiographic measure-
ments were performed in the supine position with a
commercially available echocardiographic system
(Vevo770 High Resolution Imaging System, Visual
Sonics, Toronto, Canada) using a 17.5 MHz transducer.
The transthoracic echocardiographic probe was placed
to obtain parasternal long and short-axis cardiac views.
From the cardiac long axis, an M-mode trace of the LV
was obtained, and heart rate (HR), LV end-diastolic
diameter (LVEDD), LV end-systolic diameter (LVESD),
LV posterior wall thickness (LVPW) and interventricular
septum thickness in diastole (IVS) were measured fol-
lowing the American Society of Echocardiography guide-
lines [15]. The LV ejection fraction (EF) and fractional
shortening (FS) were measured directly from the long-
axis image. Mitral inflow was recorded at the tip of the
mitral valve from a parasternal long-axis view using
Pulsed-Wave Doppler Imaging. We measured maximal
velocities of the E and A waves, isovolumic relaxation
time (IVRT, defined as the interval between the aortic
closure click and the start of mitral flow) and deceler-
ation time of the E wave (DT, the interval between the
peak early diastolic velocity and the point where the
steepest deceleration slope was extrapolated to the base-
line) [16]. E/A ratio was calculated. Using Tissue Dop-
pler Imaging, both wall movement at the level of the
lateral mitral annulus from the parasternal long-axis
view and maximal velocity of early (E0) and late (A0) dia-
stolic waves were recorded. E0/A0 and E/E0 were calcu-
lated. All measured and calculated indices are presented
as the average of three consecutive cardiac cycles. The
studies were performed by a trained echocardiographer
who was blinded to the protocol. The gained images and
data were stored and then downloaded to a magneto-
optical disk for offline analysis.
Serological studies
After echocardiography completed, adequate anaesthesia
was achieved by additional intraperitoneal administra-
tion of ketamine hydrochloride. An incision was made in
the abdomen, blood was sampled from the inferior vena
cava and kept at −80°C for subsequent assay of NT-
proBNP, IL-6 and adiponectin. Commercially available
enzyme linked immunosorbent assay (ELISA) kits (ADL
Biotechnology, Inc., USA) were used to measure serum
Figure 1 Changes in body weight (a), systolic blood pressure (b) and left ventricular mass index(c) for SHR. * p<0.05 vs. previous time
point; ** p<0.01 vs. previous time point.
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spectively according to the manufacturer’s instructions.
Because the distributions of NT-proBNP and adiponec-
tin were skewed, logarithmically transformed values
were used for statistical analysis.
Quantification of adiponectin and IL-6 mRNA expressions
After blood samples obtained, the abdominal incision
was prolonged upward to the chest, and pericardial,
perinephric and mesenteric adipose tissue samples were
harvested from each SHR and quickly stored at −80°C
for subsequent tissue study. Meanwhile, the LV was
incised, retrieved and washed in 0.9% NaCl and then
drawn up liquid by filter paper to get weighed for the
calculation of left ventricular mass index (LVMI).
Total RNA was prepared by RNA-Trizol extraction (Invi-
trogen) and treated with DNase I (Takara). cDNA was
synthesized using Reverse Transcription System (Promega,
Madison, WI, USA) according to the manufacturer's
instructions. Quantitative Real-Time PCR (qRT-PCR) ana-
lysis was performed on an iCycler system (Bio-Rad,
Hercules, CA, USA) using SYBR GREEN I as a double-
stranded DNA-specific dye according to the manufacturer's
instructions (Applied Biosystems, Foster, CA, USA). Pri-
mers were designed as follows: 50- CAG GTT GGA TGG
CAG GCA TC-30 (sense) and 50-GTA AGC GGC TTC
TCC GGG CT-30 (antisense) for rat adiponectin, 50-ACT
TCA CAA GTC GGA GGC TT-30 (sense) and 50-AGT
GCA TCA TCG CTG TTC AT-30 (antisense) for rodent
IL-6, 50- CAG TGC CAG CCT CGT CTC AT-30 (sense)
and 50-AGG GGC CAT CCA CAG TCT TC-30 (antisense)Table 1 Echocardiographic data of SHR
Chamber and wall dimensions
Month(s) LVEDD(mm) LVESD(mm) IVS(mm)
1 3.79±0.29 1.71±0.09 1.28±0.18
3 4.79±0.22** 1.89±0.09 1.60±0.09**
6 5.22±0.42** 1.95±0.07 1.79±0.11**
9 5.51±0.38** 2.60±0.24** 1.83±0.12**
12 5.61±0.25** 2.63±0.14** 2.05±0.20**
15 6.17±0.40**†† 3.61±0.16**†† 2.08±0.10**
18 5.97±0.38**† 3.72±0.20**†† 1.93±0.10**†
D
Month(s) E/A E0 /A0 E/E0
1 2.85±0.20 1.76±0.09 19.23±3.05
3 2.78±0.26 1.72±0.09 27.12±2.06**
6 2.26±0.43* 0.56±0.05** 29.66±3.64**
9 2.15±0.34** 0.63±0.07** 31.65±3.00**
12 2.19±0.32** 0.55±0.09** 35.36±4.29**
15 2.06±0.09**† 0.57±0.04** 36.93±1.31**
18 1.98±0.23**†† 0.59±0.03** 39.82±4.41**
All data are means ± SD. * p<0.05 vs. 1 month; ** p<0.01 vs. 1 month; † p<0.05 vs.for rodent GAPDH. All primers were obtained from San-
gon Biotech (Shanghai) Co., Ltd. The expression levels of
examined transcripts were compared to that of GAPDH
and normalized to the mean value of controls.Western blot analysis
The adipose tissue samples were homogenized in lysis
buffer (Cell Signalling Technology, Inc., USA) with pro-
tease inhibitor cocktail (Sigma Chemical Co., St. Louis,
MO, USA). Protein content was determined by the BCA
method. The same amounts of protein (50 μg) were
separated with denaturing SDS 10% polyacrylamide gels.
The membranes were immunoblotted with the primary
antibodies at a 1:1000 dilution followed by incubation
with secondary antibody conjugated with horseradish
peroxidase (HRP) at a 1:2000–1:5000 dilution. Bands
were visualized using ECL Western Blotting Detection
kit (Amersham Pharmacia Biotech, Piscataway, NJ).Statistical analysis
All values are expressed as means± standard deviation
(SD). Group differences were analyzed by analysis of covari-
ance (ANOVA). To compare multiple groups, Mann–
Whitney U-test with Bonferroni correction was used.
Bivariate analysis was performed to determine the correl-
ation between plasma adiponectin levels and the other con-
tinuous variables. Group differences or correlations with
p< 0.05 were considered as statistically significant. All ana-
lyses were carried out with SPSS16.0 statistical package for
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1 172.79±4.32 13.24±1.25 15.19±0.86
3 292.43±7.59** 116.09±8.78** 12.54±1.61*
6 339.43±12.59** 181.29±16.45** 12.25±0.29*
9 348.53±15.85 ** 223.61±12.43** 11.64±0.95*
12 379.18±19.37 ** 236.15±6.05 ** 9.64±0.85**






All data are means ± SD. * p<0.05 vs. 1 month; ** p<0.01 vs. 1 month; †
p<0.05 vs. 12 month; †† p<0.01 vs. 12 month.
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Body weight, systolic blood pressure and calculated left
ventricular mass index
All rats survived. Body weight of SHR increased steadily
with age and kept steady from 9 months to 18 months
of age. There was significantly elevated SBP from
110 ± 5 mmHg at 1 month to 171 ± 3 mmHg at
3 months, and reached to 195 ± 3 mmHg at 6 months,
henceforth remained plateau from 9 month to 18 month
between 195 ± 7 mmHg and 190 ± 9 mmHg. LVMI be-
came greater and greater along with the development of
hypertension and aging (Figure 1).Figure 2 Relationship between serum adiponectin with
NT-proBNP (a) and IL-6 levels (b).Echocardiographic parameters
Echocardiographic data are shown in Table 1. At
3 months of age, LV geometry of SHR demonstrated
concentric hypertrophy associated with increased
LVEDD, IVS and LVPW without change of LVESD.
LVESD exhibited a steady increase at 9 months of age.
Combined with progressively increased LVMI, an eccen-
tric LV hypertrophy was overt. These observations are
consistent with thickening of the walls between 3 and
18 months of age and a pattern of dilatation of the LV
between 9 and 18 months of age.
To examine LV systolic function of SHR, echocardio-
graphic measurements of left ventricular ejection fraction
(EF) and fractional shorting (FS) were obtained. Compared
with 1 month, both EF and FS declined at 18 months of
age, or by 3.38% and 8.75%, respectively, however, the
decreases were both statistically significant.
Diastolic function was assessed by using Pulsed-Wave
Doppler Imaging of mitral valve and Tissue Doppler Im-
aging of lateral mitral annulus. E/A ratio declined at
6 months of age, suggesting a trend toward a greater frac-
tion of ventricular filling in late diastole. Of note, E0/A0
ratio decreased sharply at 6 months of age, and remained
persistently below 1 during the rest period of study. E/E0
increased as early as at 3 months, which was in parallelwith blood pressure elevation. There were trends of pro-
longation pertaining to IVRT and DT. Hence diastolic dys-
function occurs with establishment of hypertension and
becomes apparent after 6 months of age.
Serum adiponectin level inversely correlated with
NT-proBNP and IL-6
Serum NT-proBNP level was elevated from 172.79 ± 4.32
fmol/ml at 1 month to 292.43 ± 7.59 fmol/ml at 3 months
and then fluctuated between 339.43 ± 12.59 fmol/ml
(6 months) and 407.97 ± 18.23 fmol/ml (18 months). IL-
6 increased from 13.24 ± 1.25 pg/ml (1 month) to
116.09 ± 8.78 pg/ml (3 month) and eventually to
421.45 ± 19.49 pg/ml (18 month). However, adiponectin
was initially decreased during first 3 months from
15.19 ± 0.86 ng/ml (1 month) to 12.54 ± 1.61 ng/ml
(3 months) and then reached plateau until 15 months at
10.45 ± 1.52 ng/ml compared to that of 12 months at
Table 3 Correlations of lg(adiponectin) with
echocardiographic diastolic indices
E/A E'/A' E/E' DT(ms) IVRT(ms)
r 0.683 0.671 -0.626 0.287 -0.269
P value 0.001 0.001 0.002 0.207 0.238
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nificant negative correlation was observed between
serum adiponectin and NT-proBNP levels (r =−0.756,
p < 0.001). And adiponectin level was also inversely cor-
related with IL-6 level (r =−0.635,p=0.002).Correlations of serum adiponectin level with
echocardiographic diastolic indices
As shown in Table 3, correlation analysis demonstrated
significant positive correlation between lg(adiponectin)
and E/A as well as E0/A0, while lg(adiponectin) was nega-
tively correlated with E/E0. There was no correlation
between lg(adiponectin ) with DT and IVRT.Distribution & expression of adiponectin and IL-6
There was no difference in distribution of adiponectin
among pericardial, perinephric and mesenteric adipose
tissues (Figure 3). However, with the development of left
ventricular hypertrophy and cardiac dysfunction, adipo-
nectin mRNA expression first decreased from 3 month
to 12 month and then increased at 15 month thereafter
(Figure 4). Meanwhile, IL-6 mRNA expression increased
steadily with aging (Figure 5). Adiponectin and IL-6Figure 3 Quantitative RT-PCR analysis of adiponectin mRNA
among three different locations. pc refers to pericardial adipose
tissue; pn to perinephric adipose tissue; mt to mesenteric adipose tissue.protein transcriptions were in line with mRNA expres-
sions, respectively (Figure 6).
Intraobserver reproducibility
Reproducibility of the measurement of variables
expressed as mean percent error was as follows: IVS,
1.44 ± 2.25%; EF, 5.83 ± 2.81%; FS, 6.19 ± 4.80%; E/A ratio,
0.66 ± 1.61%; E0/A0 ratio, 0.46 ± 1.26%.
Discussion
The major findings of our study were that with advent
of diastolic dysfunction since 3 month, adiponectin ex-
pression and serum concentration decreased simultan-
eously and increased at 15 month though systolic
dysfunction appeared at 18 month. We also demon-
strated no distribution differences of adiponectin among
visceral adipose tissues.
SHR is a well established hypertension model similar
to human hypertension such as the occurrence of LV
hypertrophy followed by a transition to heart failure
[17]. Therefore SHR has been regarded as a useful tool
for studying the disease progression and mechanisms of
LV hypertrophy and heart failure [18]. Echocardiography
is one of the most widely used as a non-invasive tech-
nique to provide quantitative measurements of ventricu-
lar structure and function in humans and experimental
animals. High-frequency transducers (17.5 MHz) was
used in our study, which greatly overcame the difficulties
of a small weight of around ~1 g with 2 mm LV wall
thickness in rats and a rapid heart rate of 300–400 bpm,
providing high resolution images for morphometric and
functional measurements [19,20].
It is clear during the development of hypertension,
alteration in LV geometry occurs as an early adaptation
to increasing pressure and volume overload. In our
study, during first 3 months, LVEDD, IVS and LVPW
were increased whereas LVESD remain unchanged,
indicating concentric hypertrophy. In the mean time
cardiac function as assessed by echocardiography in
terms of EF and FS was kept unchanged until
18 months. Meanwhile, diastolic dysfunction became
overt from 6 month with decreased E/A ratio and E0/A0
ratio. However IVRT and DT values didn’t alter possibly
due to high heart rate [21].
As a key functional abnormality in diastolic dysfunc-
tion and heart failure, abnormal diastolic filling pressure
leads to a release of natriuretic peptides including NT-
proBNP, which was released predominantly by the ven-
tricles in response to stretch [22]. NT-proBNP levels
increased significantly according to the severity of over-
all diastolic dysfunction, ranging from impaired relax-
ation to pseudonormal filling and restrictive filling,
however, the role of NT-proBNP in patients with dia-
stolic heart failure is still under investigation [23,24].
Figure 4 Quantitative RT-PCR analysis of adiponectin mRNA with disease progression. * p<0.05 vs. 1 month; ** p<0.01 vs. 1 month;
† p<0.05 vs. 12 month; †† p<0.01 vs. 12 month.
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with diastolic abnormalities in patients with reduced
systolic function [25] and in patients with advanced
forms of isolated diastolic heart failure [26,27], several
Doppler echocardiographic studies found them not to
be useful for the detection of mild diastolic dysfunction.
The latter is associated with increased filling pressures
at exertion only and will be missed by conventional
Doppler echocardiography, which is performed at rest.Figure 5 Quantitative RT-PCR analysis of IL-6 mRNA with disease pro
† p<0.05 vs. 12 month; †† p<0.01 vs. 12 month.Documented data indicated that chronic inflammation
is closely associated with the development of cardiovas-
cular and cardiovascular-related disorders, such as
hypertension, heart failure, etc. Adipokines secreted
from adipose tissue, such as leptin and interleukin-6
(IL-6) showed significant contribution to the positive
regulation of inflammatory.
It is reported that low levels of adiponectin was asso-
ciated with a further progression of left ventriculargression. * p<0.05 vs. 1 month; ** p<0.01 vs. 1 month;
Figure 6 Representative western blots (a) and qualification of adiponectin and IL-6 protein expressions with disease progression (b, c).
* p<0.05 vs. 1 month; ** p<0.01 vs. 1 month; † p<0.05 vs. 12 month; †† p<0.01 vs. 12 month.
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ventricular diastolic dysfunction and hypertrophy [28].
Our data are in line with such reports describing an asso-
ciation between decreasing levels of adiponectin serum
concentration and increasing hypertension. In current
study we determined multiple biomarkers including
NT-proBNP, IL-6 and adiponectin at multiple time
points during transition period from hypertension to
heart dysfunction. Reason for choosing a combination
of biomarkers such as NT-proBNP, IL-6 and adiponec-
tin is to cover different pathophysiological mechanisms
such as cardiac stress, inflammation and adipocytokines.
Our results have shown that, being different from
NT-proBNP and IL-6 which keep increasing during pro-
gression of heart dysfunction, adiponectin was decreased
from 3 month when diastolic dysfunction occurred and
then increased at 15 month prior to advent of systolic
dysfunction which was apparent at 18 month. Therefore
adiponectin is the biomarker indicating onset rather
than progression of heart dysfunction. In contrast,
NT-proBNP and IL-6 are biomarkers not only for onset
of heart dysfunction but also progression of heart dys-
function. Though our animal model is mainly hyperten-
sion induced heart dysfunction rather than heart failure,
as is evidenced in other studies [29,30], serum adiponec-
tin level was elevated in chronic heart failure, our study
also witnessed a trend.
Finally, adiponectin is produced exclusively by adipo-
cytes [31] and its concentrations were predominantly
determined by visceral fat [32]. However, up to now, dif-
ference in adiponectin gene expression in relation to vari-
ous adipose tissue depots is still not fully elucidated [33].
Our study demonstrated no difference in adiponectin dis-
tribution, at least among pericardial, perinephric and mes-
enteric adipose tissues. However, adiponectin expression
and serum level decreased with cardiac diastolic dysfunc-
tion and increased prior to systolic dysfunction while not
in line with systolic dysfunction. We speculated the rea-
sons might be as follows: (1) with disease progression,
renal and hepatic functions might be impaired, and the
clearance of adiponectin might also decrease [34,35], com-
bined with relatively increased adiponectin expression,
resulting in a prior serum elevation, which is partially con-
sistent with our observations; (2) adiponectin is present in
plasma in different isoforms: a large multimeric structure
of high molecular weight and in a trimer and examer
form, whereas the monomeric form is not found in
peripheral circulation but only in the adipose tissue.
Moreover, the lipolysis in adipose cells appears to be hor-
mone-dependent, catecholamines and natriuretic peptides,
besides insulin, exerting important effects [36]. (3) Circu-
lating adiponectin concentrations can be regulated by vari-
ous hormonal, nutritional and pharmacological factors. In
heart dysfunction there are increased levels of IL-6 andTNF-α, as evidenced in our study, which might lead to de-
crease in serum adiponectin levels [37] and it is also
reported adiponectin gene expression is reversibly down-
regulated by IL-6 [38]. The precise mechanism still needs
further investigation.
In conclusion, we demonstrated that serum adiponectin
level may be a useful biomarker during transition from
hypertension to onset of cardiac dysfunction and adipo-
nectin level is tempting to serve as a valuable indicator for
early intervention. However, effectiveness and specificity
are the two basic characteristics for a useful biomarker.
The establishment of adiponectin as a valuable biomarker
needs practical examination. Hence, whether and to what
extent adiponectin could be used as a practical biomarker
for cardiac function transition need more studies espe-
cially clinical data to support and prove and cautions
should be take when making such conclusions.
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